{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:13:46Z","timestamp":1773234826414,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI122377-01"],"award-info":[{"award-number":["AI122377-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI143567-02"],"award-info":[{"award-number":["AI143567-02"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI124823-02"],"award-info":[{"award-number":["R21AI124823-02"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI055434-11"],"award-info":[{"award-number":["T32AI055434-11"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["CSDA201612"],"award-info":[{"award-number":["CSDA201612"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002538"],"award-info":[{"award-number":["UL1TR002538"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bcp.2021.114844","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T10:50:05Z","timestamp":1637232605000},"page":"114844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation"],"prefix":"10.1016","volume":"195","author":[{"given":"Erin T.","family":"Larragoite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Racheal A.","family":"Nell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis R.","family":"Barrows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Planelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M.","family":"Spivak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bcp.2021.114844_b0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2021.114844_b0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"6629","key":"10.1016\/j.bcp.2021.114844_b0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"Perelson","year":"1997","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.bcp.2021.114844_b0020","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5341","key":"10.1016\/j.bcp.2021.114844_b0025","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science (New York, NY)."},{"issue":"5341","key":"10.1016\/j.bcp.2021.114844_b0030","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","volume":"278","author":"Wong","year":"1997","journal-title":"Science (New York, NY)."},{"key":"10.1016\/j.bcp.2021.114844_b0035","series-title":"The Future of HIV-1 Therapeutics-Resistance is Futile","year":"2015"},{"issue":"6","key":"10.1016\/j.bcp.2021.114844_b0040","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/QAD.0b013e3283360976","article-title":"The high cost of second-line antiretroviral therapy for HIV\/AIDS in South Africa","volume":"24","author":"Long","year":"2010","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.bcp.2021.114844_b0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/apc.2014.0255","article-title":"Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants","volume":"29","author":"Saberi","year":"2015","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"10.1016\/j.bcp.2021.114844_b0050","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/apc.2006.20.359","article-title":"Social stigma concerns and HIV medication adherence","volume":"20","author":"Rintamaki","year":"2006","journal-title":"AIDS Patient Care STDS"},{"issue":"3 Suppl 2","key":"10.1016\/j.bcp.2021.114844_b0055","doi-asserted-by":"crossref","first-page":"18640","DOI":"10.7448\/IAS.16.3.18640","article-title":"Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis","volume":"16","author":"Katz","year":"2013","journal-title":"J Int AIDS Soc."},{"issue":"8","key":"10.1016\/j.bcp.2021.114844_b0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri3262","article-title":"Towards an HIV cure: a global scientific strategy","volume":"12","author":"International ASSWGoHIVC","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/COH.0000000000000025","article-title":"Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk","volume":"9","author":"Borges","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2021.114844_b0070","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/QAI.0b013e31825a3668","article-title":"HIV OARWGo, Aging. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group","volume":"60","author":"High","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"9","key":"10.1016\/j.bcp.2021.114844_b0075","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2013.53.1376","article-title":"Moving forward in HIV-associated cancer","volume":"32","author":"Gopal","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0080","first-page":"54","article-title":"HIV-associated neurocognitive disorders (HAND)","volume":"17","author":"Elbirt","year":"2015","journal-title":"Isr. Med. Assoc. J."},{"issue":"7408","key":"10.1016\/j.bcp.2021.114844_b0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molmed.2015.11.004","article-title":"HIV-1 eradication: early trials (and tribulations)","volume":"22","author":"Spivak","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu. Rev. Immunol."},{"issue":"4-5","key":"10.1016\/j.bcp.2021.114844_b0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cytogfr.2012.05.001","article-title":"The role of cytokines in the establishment, persistence and eradication of the HIV reservoir","volume":"23","author":"Vandergeeten","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"issue":"43","key":"10.1016\/j.bcp.2021.114844_b0105","doi-asserted-by":"crossref","first-page":"36609","DOI":"10.1074\/jbc.M112.410746","article-title":"Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein","volume":"287","author":"Bartholomeeusen","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2021.114844_b0110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02328-19","article-title":"Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-kappaB Pathways Mediated by Heat Shock Response","volume":"64","author":"Peng","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1084\/jem.188.1.83","article-title":"Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines","volume":"188","author":"Chun","year":"1998","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.bcp.2021.114844_b0120","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1172\/JCI92684","article-title":"Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency","volume":"127","author":"Archin","year":"2017","journal-title":"J Clin Invest."},{"issue":"16","key":"10.1016\/j.bcp.2021.114844_b0125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92901","article-title":"HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal","volume":"2","author":"Wu","year":"2017","journal-title":"JCI Insight."},{"key":"10.1016\/j.bcp.2021.114844_b0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fphar.2020.00905","article-title":"Novel histone deacetylase inhibitors and HIV-1 latency-reversing agents identified by large-scale virtual screening","volume":"11","author":"Divsalar","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114844_b0135","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","article-title":"Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations","volume":"125","author":"Laird","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bcp.2021.114844_b0140","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1128\/AAC.01077-15","article-title":"Ex Vivo bioactivity and HIV-1 latency reversal by ingenol dibenzoate and panobinostat in resting CD4(+) T Cells from aviremic patients","volume":"59","author":"Spivak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.bcp.2021.114844_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003834","article-title":"An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients","volume":"9","author":"Spina","year":"2013","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.bcp.2021.114844_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005063","article-title":"An In-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression","volume":"11","author":"Darcis","year":"2015","journal-title":"PLoS Pathog."},{"issue":"17","key":"10.1016\/j.bcp.2021.114844_b0155","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1074\/jbc.270.17.9833","article-title":"Analysis of the role of protein kinase C-alpha, -epsilon, and -zeta in T cell activation","volume":"270","author":"Genot","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2021.114844_b0160","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.1128\/JVI.76.16.8118-8123.2002","article-title":"Effects of prostratin on T-cell activation and human immunodeficiency virus latency","volume":"76","author":"Korin","year":"2002","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0165","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12977-016-0319-0","article-title":"Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo","volume":"13","author":"Spivak","year":"2016","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.bcp.2021.114844_b0170","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI89552","article-title":"Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity","volume":"127","author":"Martin","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bcp.2021.114844_b0175","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3390\/v13102037","article-title":"The novel PKC activator 10-methyl-aplog-1 combined with JQ1 induced strong and synergistic HIV reactivation with tolerable global T cell activation","volume":"13","author":"Washizaki","year":"2021","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.bcp.2021.114844_b0180","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1073\/pnas.0400380101","article-title":"Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect","volume":"101","author":"Reddy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bcp.2021.114844_b0185","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.4049\/jimmunol.0901467","article-title":"Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue","volume":"184","author":"Grabiec","year":"2010","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114844_b0190","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines","volume":"99","author":"Leoni","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bcp.2021.114844_b0195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/157016210793499312","article-title":"Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency","volume":"8","author":"Perez","year":"2010","journal-title":"Curr. HIV Res."},{"issue":"11","key":"10.1016\/j.bcp.2021.114844_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113341","article-title":"Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.bcp.2021.114844_b0205","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1535-7163.MCT-06-0782","article-title":"CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling","volume":"6","author":"Evelyn","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bcp.2021.114844_b0210","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood.V98.10.3006","article-title":"Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART","volume":"98","author":"Kulkosky","year":"2001","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.bcp.2021.114844_b0215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11010-010-0543-1","article-title":"Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis","volume":"344","author":"You","year":"2010","journal-title":"Mol. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.bcp.2021.114844_b0220","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1634\/theoncologist.2007-0190","article-title":"Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells","volume":"13","author":"Ning","year":"2008","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bcp.2021.114844_b0225","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1535-7163.425.3.4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells","volume":"3","author":"Zhang","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.bcp.2021.114844_b0230","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1073\/pnas.88.13.5542","article-title":"Potent cytodifferentiating agents related to hexamethylenebisacetamide","volume":"88","author":"Breslow","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2021.114844_b0235","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3389\/fmicb.2016.01970","article-title":"Histone deacetylase inhibitors reduce the number of herpes simplex virus-1 genomes initiating expression in individual cells","volume":"7","author":"Shapira","year":"2016","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114844_b0240","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jnc.14144","article-title":"Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism","volume":"143","author":"Durham","year":"2017","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.bcp.2021.114844_b0245","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjp.0707165","article-title":"Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents","volume":"150","author":"Lin","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0250","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuroscience.2010.04.074","article-title":"MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis","volume":"169","author":"Zhang","year":"2010","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/nar\/gks916","article-title":"The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-kappaB","volume":"41","author":"Ziesche","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2021.114844_b0260","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.58","article-title":"Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression","volume":"4","author":"Oki","year":"2014","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.bcp.2021.114844_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079502","article-title":"The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines","volume":"8","author":"Klein","year":"2013","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.bcp.2021.114844_b0270","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.3390\/ijms21238943","article-title":"Inhibition of HDAC enzymes contributes to differential expression of pro-inflammatory proteins in the TLR-4 signaling cascade","volume":"21","author":"Weiss","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7408","key":"10.1016\/j.bcp.2021.114844_b0275","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bcp.2021.114844_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"Elliott","year":"2014","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0285","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.bcp.2021.114844_b0290","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nm.3489","article-title":"New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo","volume":"20","author":"Bullen","year":"2014","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114844_b0295","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-016-0268-7","article-title":"In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection","volume":"13","author":"Tsai","year":"2016","journal-title":"Retrovirology"},{"issue":"4","key":"10.1016\/j.bcp.2021.114844_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004071","article-title":"Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing","volume":"10","author":"Wei","year":"2014","journal-title":"PLoS Pathog."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:24:24Z","timestamp":1757769864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221004603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":60,"alternative-id":["S0006295221004603"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114844","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/193946","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114844"}}